Antimetastatic effects of a soluble IL-33 receptor and its utility as a prognostic biomarker in colorectal cancer.
| Project/Area Number |
24791422
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Shimane University |
|---|
Principal Investigator |
AKIMOTO Miho 島根大学, 医学部, 助教 (60437556)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Keywords | 転移抑制 / がん微小環境 / 大腸がん / サイトカイン / 予後予測 |
|---|
| Outline of Final Research Achievements |
Our studies revealed that the expression of sST2, a soluble receptor for IL-33, in human and mouse colorectal cancer cells suppress sporadic metastasis via modulating inflammatory tumormicroenvironments. Importantly, the administration of recombinant sST2 showed antitumor and antimetastatic effects in human or mouse colon tumor-bearing mice. Our results also indicated that ST2 expression levels in tumor tissues may be an effective prognostic biomarker in colon cancer. Collectively, our studies demonstrate the potential for developing novel ST2-based therapeutic and diagnostic strategies for colorectal cancer.
|
Report
(4 results)
Research Products
(17 results)
